October 30, 2023

WATCH: Capricor Therapeutics – CAP-1002 HOPE-3 Program Update (Webinar Recording)

PPMD and Capricor Therapeutics held a community webinar on October 25, 2023 to provide an overview of the latest regulatory developments for Capricor’s ongoing HOPE-3 Phase 3 study of CAP-1002, the company’s cell therapy. Capricor’s…

Learn More

January 31, 2023

WATCH: Capricor Data Update From Ongoing HOPE-2 Open Label Extension Trial – Webinar Recording

WATCH: Capricor Data Update From Ongoing HOPE-2 Open Label Extension Trial Capricor Therapeutics recently joined PPMD for a community webinar on January 25, 2023 to present recent data findings from the ongoing HOPE-2 open label…

Learn More

June 27, 2022

Capricor Announces Positive One-Year Results from HOPE-2 Open Label Extension Study Evaluating CAP-1002

Dr. Linda Marbán, CEO of Capricor Therapeutics, presented a Late-Breaking News session at PPMD’s 2022 Annual Conference, announcing positive 1-year efficacy results from the ongoing HOPE-2 open label extension study of CAP-1002 in non-ambulant Duchenne…

Learn More

March 14, 2022

The Lancet Publishes Positive Results from Capricor’s Phase 2 Study of CAP-1002 in Late-Stage Duchenne

Capricor Therapeutics has announced that The Lancet has published positive results from the company’s HOPE-2 Phase 2 clinical trial evaluating CAP-1002 in advanced stages of Duchenne. Findings from the study demonstrated that young men in the advanced stages…

Learn More

January 25, 2022

Capricor & Nippon Shinyaku Enter Partnership for Commercialization and Distribution of CAP-1002 in the U.S.

Capricor Therapeutics and Nippon Shinyaku (US subsidiary: NS Pharma) have announced that they have entered into an agreement for the exclusive commercialization and distribution in the United States of CAP-1002, Capricor’s novel cell therapy candidate…

Learn More

September 24, 2021

Capricor Therapeutics Announces Positive Final Data From its Phase II HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002

PPMD is pleased to share that Capricor Therapeutics announced today positive final data from the HOPE-2 randomized, double-blind, placebo controlled clinical trial using CAP-1002 to treat patients with Duchenne. The HOPE-2 clinical trial met its…

Learn More

June 4, 2020

WATCH: Capricor’s HOPE-2 Final 12-Month Data – Webinar Recording

Capricor Therapeutics recently announced positive final 12-month results from the HOPE-2 Trial. HOPE-2 was a randomized, double-blind, placebo-controlled study focused on later-stage Duchenne patients. On June 3, 2020, Capricor joined PPMD for a webinar to…

Learn More

May 13, 2020

Capricor Announces Positive Top-Line Final Results from HOPE-2 Study

PPMD is excited to learn that Capricor Therapeutics has announced positive top-line 12-month results of the HOPE-2 clinical trial using CAP-1002 to treat non-ambulatory patients with Duchenne. Capricor has reported that the placebo patients in…

Learn More

October 9, 2019

2019 World Muscle Society Update – Day 4

This week, PPMD’s Abby Bronson, SVP of Research Strategy and Eric Camino, PhD, Director of Research and Clinical Innovation are attending the annual World Muscle Society (WMS) meeting, this year in Copenhagen, Denmark. Below, Abby…

Learn More

October 7, 2019

2019 World Muscle Society Update – Days 2 & 3

This week, PPMD’s Abby Bronson, SVP of Research Strategy and Eric Camino, PhD, Director of Research and Clinical Innovation are attending the annual World Muscle Society (WMS) meeting, this year in Copenhagen, Denmark. Below, Abby…

Learn More